The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside

Abstract

Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. Methods: Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. Conclusions: In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.

Keywords: biomarkers; biosensors; biotechnology; cancer-diagnostics; early-detection; lung cancer; machine-learning; pulmonary; screening; volatile organic compounds.

Figure 1

(A–D) Computed tomography and PET-CT scans of the presented patients. (A1) The arrow marks the suspicious cavitary lesion in the major fissure extending from the RLL to the RUL. (A2) The arrow marks the central hypermetabolic FDG avid nodule in the RLL. (B1) The arrow marks the apical mass in the vicinity of the emphysematous lung. (C1) The arrow marks the peripheral consolidation (on biopsy: chronic inflammation). (C2) The arrow marks the peripheral hypermetabolic FDG avid consolidation (on biopsy: chronic inflammation). (D1) The arrow marks a central hypermetabolic FDG avid nodule near the segmental pulmonary artery (biopsy was negative for tumor). (D2) The arrow marks central nodule (biopsy was negative for tumor).